Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for MIRABEGRON
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
- Management of OAB in Female Patients .
- A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
- Acupuncture Combined With Mirabegron in the Treatment of OAB
- Using Mirabegron to Increase BP in Patients With POTS
- THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS
- Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
- MIrabegron and Physiological Function in Cold Environments
- Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
- Effect of Mirabegron on Promoting Brown Adipose Tissue Activation
- Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / As
- Effect of Mirabegron on Bladder Compliance
- Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
- ADRB3 Signaling Pathway in Human Adipose Tissue
- A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity
- Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
- Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women
- Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)
- Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB
- Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation
- Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
- Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
- TReating Incontinence for Underlying Mental and Physical Health
- Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children
- Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
- Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
- The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
- Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder
- Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
- Activation of Brown Adipose Tissue Metabolism Using Mirabegron
- Mirabegron and Physiological Function in Cold Environments
- Mechanisms for Activation of Beige Adipose Tissue in Humans
- A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
- A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
- A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants
- A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
- Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)
- Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms
- Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
- Mirabegron And Ureteral Stent-related Pain (MAP) Trial
- Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
- Beta 3 Agonist Treatment in Heart Failure-2
- Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
- Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
- Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
- Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
- Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
- Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
- Trigonal vs Non Trigonal Botox Injection in OAB.
- Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease
- Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study
- Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
- Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury
- Study of ONO-8577 in Patients With Overactive Bladder
- Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder
- Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta 3-Adrenergic Receptor Agonists
- Mirabegron and Brown Adipose Tissue
- Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
- Brown Fat Activation Study
- Mirabegron For Erectile Dysfunction
- The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
- Pharmacological Activation of Brown Adipose Tissue Metabolism
- A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
- Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
- Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
- A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
- Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists
- Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
- Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
- Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
- Mirabegron in Parkinson Disease and Impaired Cognition
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
- Mirabegron and Urinary Urgency Incontinence
- Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
- Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
- Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
- Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
- Treatment of Incontinence Without Memory Problems
- Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- MIrabegron With oveRACtive bLadder Symptoms in mEn
- Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults
- A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
- Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
- Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
- Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
- Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
- A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
- Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
- Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
- A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
- Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
- A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
- Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
- A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
- This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
- Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
- Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
- Drug Use-Results Survey of Betanis Tablets in Japan
- A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
- Long-Term Specified Drug Use-results Survey of Betanis Tablets
- Specified Drug Use-results Survey of Betanis Tablets
- Beta 3 Agonist Treatment in Heart Failure
- A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects
- A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
- Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
- A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178
- A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178
- A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions
- A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
- Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
- A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
- A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
- To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
- A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation
- To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females
- To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol
- A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers
- A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
- A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers
- A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
- A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill
- A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex
- A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
- A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
- A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
- A Study of YM178 in Subjects With Symptoms of Overactive Bladder
- A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
- A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers
- Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron
- Study of the Effect of Food on the Pharmacokinetics of Mirabegron
- A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
- Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
- A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
Clinical trials list
click for details